Scientific

MK5 Microarray Data

Affected Genes - Ontology Breakdown - Gene Enrichment - Proteome Analysis

These are the micro-array results of a differential gene expression microarray experiments and the subsequent analysis steps performed on them. The up/down- regulation ratio was obtained by measuring WT cells against MK5 activated cells. See material and methods for technical information as well as the data usage policy.

MK5 Proteome Analysis - Divided Values

Type II network, divided values. Interestingly most of the proteins in the first 100 positions in this table would occur in the divided ranks table between position 100 and 200, indicating a difference in emphasis between the two simulations but not in the overall function. The fully annotated table, include Ensembl gene identifiers and network values can be found in the supplementary data.


Navigation/Query Panel:
Click on the attribute name to hide/unhide it. The green arrows can be used to shift columns left/right. Exact word match is written as =..., regular expressions can be matched with ~.... To select all values larger or equal than use >.... This would be <... for values smaller or equal than. To select all values within a specific range use [...,...].
Filtered Value Type Gene green Rank description Interaction Map Network Comparison Type network_comparison red
Results: HTML CSV LaTeX Showing element 101 to 150 of 77072 in total 
Filtered: 0
Value Type: Measured

\def\wcA{0.125\textwidth}
\def\wcB{0.125\textwidth}
\def\wcC{0.125\textwidth}
\def\wcD{0.125\textwidth}
\def\wcE{0.125\textwidth}
\def\wcF{0.125\textwidth}
\def\wcG{0.125\textwidth}
\begin{longtable}{|c|c|c|c|c|c|c|}
\hline
\parbox{\wcA}{\vspace{3pt}\noindent
green\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
Rank\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
description\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
Interaction Map\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
Network Comparison Type\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
network\_comparison\vspace{3pt}}&\parbox{\wcG}{\vspace{3pt}\noindent
red\vspace{3pt}}\\
\hline
\hline
\multirow{2}{*}{\parbox{\wcA}{\vspace{3pt}\noindent
29\vspace{3pt}}}&\parbox{\wcB}{\vspace{3pt}\noindent
83\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
abl-philin 2. [source:refseq;acc:nm\_032327]\vspace{3pt}}}&\multirow{42}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
Low confidence\vspace{3pt}}}&\parbox{\wcE}{\vspace{3pt}\noindent
Divided\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.65517\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcG}{\vspace{3pt}\noindent
48\vspace{3pt}}}\\\cline{2-2}\cline{5-6}
&\parbox{\wcB}{\vspace{3pt}\noindent
746\vspace{3pt}}&&&\parbox{\wcE}{\vspace{3pt}\noindent
Subtracted\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
19\vspace{3pt}}&\\\cline{1-3}\cline{5-7}
\multirow{2}{*}{\parbox{\wcA}{\vspace{3pt}\noindent
31\vspace{3pt}}}&\parbox{\wcB}{\vspace{3pt}\noindent
412\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
adapter-related protein complex 2 alpha 1 subunit (alpha-adaptin a) (adaptor protein complex ap-2 alpha-1 subunit) (clathrin assembly protein complex 2 alpha-a large chain) (100 kda coated vesicle protein a) (plasma membrane adaptor ha2/ap2 adaptin alpha a subunit). [source:swissprot;acc:o95782]\vspace{3pt}}}&&\parbox{\wcE}{\vspace{3pt}\noindent
Divided\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.09677\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcG}{\vspace{3pt}\noindent
34\vspace{3pt}}}\\\cline{2-2}\cline{5-6}
&\parbox{\wcB}{\vspace{3pt}\noindent
813\vspace{3pt}}&&&\parbox{\wcE}{\vspace{3pt}\noindent
Subtracted\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
3\vspace{3pt}}&\\\cline{1-3}\cline{5-7}
\multirow{34}{*}{\parbox{\wcA}{\vspace{3pt}\noindent
35.5\vspace{3pt}}}&\parbox{\wcB}{\vspace{3pt}\noindent
27\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
melanoma antigen, family d, 4 isoform 1; mage1 protein; mage-e1 protein; maged4 protein. [source:refseq;acc:nm\_030801]\vspace{3pt}}&&\multirow{17}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
Divided\vspace{3pt}}}&\multirow{17}{*}{\parbox{\wcF}{\vspace{3pt}\noindent
2.97183\vspace{3pt}}}&\multirow{34}{*}{\parbox{\wcG}{\vspace{3pt}\noindent
105.5\vspace{3pt}}}\\\cline{2-3}
&\parbox{\wcB}{\vspace{3pt}\noindent
28\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
melanoma-associated antigen 3 (mage-3 antigen) (antigen mz2-d). [source:swissprot;acc:p43357]\vspace{3pt}}&&&&\\\cline{2-3}
&\parbox{\wcB}{\vspace{3pt}\noindent
29\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
melanoma-associated antigen 11 (mage-11 antigen). [source:swissprot;acc:p43364]\vspace{3pt}}&&&&\\\cline{2-3}
&\parbox{\wcB}{\vspace{3pt}\noindent
30\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
melanoma-associated antigen 2 (mage-2 antigen). [source:swissprot;acc:p43356]\vspace{3pt}}&&&&\\\cline{2-3}
&\parbox{\wcB}{\vspace{3pt}\noindent
31\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
hepatocellular carcinoma-associated protein hca1. [source:refseq;acc:nm\_020932]\vspace{3pt}}&&&&\\\cline{2-3}
&\parbox{\wcB}{\vspace{3pt}\noindent
32\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
melanoma-associated antigen 6 (mage-6 antigen) (mage3b). [source:swissprot;acc:p43360]\vspace{3pt}}&&&&\\\cline{2-3}
&\parbox{\wcB}{\vspace{3pt}\noindent
33\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
melanoma-associated antigen d1 (mage-d1 antigen) (neurotrophin receptor-interacting mage homolog) (pro2292). [source:swissprot;acc:q9y5v3]\vspace{3pt}}&&&&\\\cline{2-3}
&\parbox{\wcB}{\vspace{3pt}\noindent
34\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
melanoma-associated antigen f1 (mage-f1 antigen). [source:swissprot;acc:q9hay2]\vspace{3pt}}&&&&\\\cline{2-3}
&\parbox{\wcB}{\vspace{3pt}\noindent
35\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
melanoma-associated antigen 4 (mage-4 antigen) (mage-x2) (mage-41). [source:swissprot;acc:p43358]\vspace{3pt}}&&&&\\\cline{2-3}
&\parbox{\wcB}{\vspace{3pt}\noindent
36\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
melanoma-associated antigen 9 (mage-9 antigen). [source:swissprot;acc:p43362]\vspace{3pt}}&&&&\\\cline{2-3}
&\parbox{\wcB}{\vspace{3pt}\noindent
37\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
melanoma-associated antigen 8 (mage-8 antigen). [source:swissprot;acc:p43361]\vspace{3pt}}&&&&\\\cline{2-3}
&\parbox{\wcB}{\vspace{3pt}\noindent
38\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
melanoma-associated antigen c1 (mage-c1 antigen) (cancer-testis antigen ct7). [source:swissprot;acc:o60732]\vspace{3pt}}&&&&\\\cline{2-3}
&\parbox{\wcB}{\vspace{3pt}\noindent
39\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
melanoma-associated antigen 12 (mage-12 antigen) (mage12f). [source:swissprot;acc:p43365]\vspace{3pt}}&&&&\\\cline{2-3}
&\parbox{\wcB}{\vspace{3pt}\noindent
40\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
melanoma-associated antigen 1 (mage-1 antigen) (antigen mz2-e). [source:swissprot;acc:p43355]\vspace{3pt}}&&&&\\\cline{2-3}
&\parbox{\wcB}{\vspace{3pt}\noindent
41\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
melanoma-associated antigen 10 (mage-10 antigen). [source:swissprot;acc:p43363]\vspace{3pt}}&&&&\\\cline{2-3}
&\parbox{\wcB}{\vspace{3pt}\noindent
42\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
melanoma-associated antigen b1 (mage-b1 antigen) (mage-xp antigen) (dss-ahc critical interval mage superfamily 10) (dam10). [source:swissprot;acc:p43366]\vspace{3pt}}&&&&\\\cline{2-3}
&\parbox{\wcB}{\vspace{3pt}\noindent
43\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
melanoma-associated antigen d2 (mage-d2 antigen) (breast cancer associated gene 1 protein) (bcg-1) (11b6) (hepatocellular carcinoma associated protein jcl-1). [source:swissprot;acc:q9unf1]\vspace{3pt}}&&&&\\\cline{2-3}\cline{5-6}
&\parbox{\wcB}{\vspace{3pt}\noindent
512\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
melanoma antigen, family d, 4 isoform 1; mage1 protein; mage-e1 protein; maged4 protein. [source:refseq;acc:nm\_030801]\vspace{3pt}}&&\multirow{17}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
Subtracted\vspace{3pt}}}&\multirow{17}{*}{\parbox{\wcF}{\vspace{3pt}\noindent
70\vspace{3pt}}}&\\\cline{2-3}
&\parbox{\wcB}{\vspace{3pt}\noindent
513\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
melanoma-associated antigen 3 (mage-3 antigen) (antigen mz2-d). [source:swissprot;acc:p43357]\vspace{3pt}}&&&&\\\cline{2-3}
&\parbox{\wcB}{\vspace{3pt}\noindent
514\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
melanoma-associated antigen 11 (mage-11 antigen). [source:swissprot;acc:p43364]\vspace{3pt}}&&&&\\\cline{2-3}
&\parbox{\wcB}{\vspace{3pt}\noindent
515\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
melanoma-associated antigen 2 (mage-2 antigen). [source:swissprot;acc:p43356]\vspace{3pt}}&&&&\\\cline{2-3}
&\parbox{\wcB}{\vspace{3pt}\noindent
516\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
hepatocellular carcinoma-associated protein hca1. [source:refseq;acc:nm\_020932]\vspace{3pt}}&&&&\\\cline{2-3}
&\parbox{\wcB}{\vspace{3pt}\noindent
517\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
melanoma-associated antigen 6 (mage-6 antigen) (mage3b). [source:swissprot;acc:p43360]\vspace{3pt}}&&&&\\\cline{2-3}
&\parbox{\wcB}{\vspace{3pt}\noindent
518\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
melanoma-associated antigen d1 (mage-d1 antigen) (neurotrophin receptor-interacting mage homolog) (pro2292). [source:swissprot;acc:q9y5v3]\vspace{3pt}}&&&&\\\cline{2-3}
&\parbox{\wcB}{\vspace{3pt}\noindent
519\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
melanoma-associated antigen f1 (mage-f1 antigen). [source:swissprot;acc:q9hay2]\vspace{3pt}}&&&&\\\cline{2-3}
&\parbox{\wcB}{\vspace{3pt}\noindent
520\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
melanoma-associated antigen 4 (mage-4 antigen) (mage-x2) (mage-41). [source:swissprot;acc:p43358]\vspace{3pt}}&&&&\\\cline{2-3}
&\parbox{\wcB}{\vspace{3pt}\noindent
521\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
melanoma-associated antigen 9 (mage-9 antigen). [source:swissprot;acc:p43362]\vspace{3pt}}&&&&\\\cline{2-3}
&\parbox{\wcB}{\vspace{3pt}\noindent
522\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
melanoma-associated antigen 8 (mage-8 antigen). [source:swissprot;acc:p43361]\vspace{3pt}}&&&&\\\cline{2-3}
&\parbox{\wcB}{\vspace{3pt}\noindent
523\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
melanoma-associated antigen c1 (mage-c1 antigen) (cancer-testis antigen ct7). [source:swissprot;acc:o60732]\vspace{3pt}}&&&&\\\cline{2-3}
&\parbox{\wcB}{\vspace{3pt}\noindent
524\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
melanoma-associated antigen 12 (mage-12 antigen) (mage12f). [source:swissprot;acc:p43365]\vspace{3pt}}&&&&\\\cline{2-3}
&\parbox{\wcB}{\vspace{3pt}\noindent
525\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
melanoma-associated antigen 1 (mage-1 antigen) (antigen mz2-e). [source:swissprot;acc:p43355]\vspace{3pt}}&&&&\\\cline{2-3}
&\parbox{\wcB}{\vspace{3pt}\noindent
526\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
melanoma-associated antigen 10 (mage-10 antigen). [source:swissprot;acc:p43363]\vspace{3pt}}&&&&\\\cline{2-3}
&\parbox{\wcB}{\vspace{3pt}\noindent
527\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
melanoma-associated antigen b1 (mage-b1 antigen) (mage-xp antigen) (dss-ahc critical interval mage superfamily 10) (dam10). [source:swissprot;acc:p43366]\vspace{3pt}}&&&&\\\cline{2-3}
&\parbox{\wcB}{\vspace{3pt}\noindent
528\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
melanoma-associated antigen d2 (mage-d2 antigen) (breast cancer associated gene 1 protein) (bcg-1) (11b6) (hepatocellular carcinoma associated protein jcl-1). [source:swissprot;acc:q9unf1]\vspace{3pt}}&&&&\\\cline{1-3}\cline{5-7}
\multirow{4}{*}{\parbox{\wcA}{\vspace{3pt}\noindent
37\vspace{3pt}}}&\parbox{\wcB}{\vspace{3pt}\noindent
74\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
arf gtpase-activating protein. [source:refseq;acc:nm\_133446]\vspace{3pt}}&&\multirow{2}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
Divided\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcF}{\vspace{3pt}\noindent
1.78378\vspace{3pt}}}&\multirow{4}{*}{\parbox{\wcG}{\vspace{3pt}\noindent
66\vspace{3pt}}}\\\cline{2-3}
&\parbox{\wcB}{\vspace{3pt}\noindent
75\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
up-regulated in liver cancer 1; similar to development- and differentiation-enhancing factor 2. [source:refseq;acc:nm\_017707]\vspace{3pt}}&&&&\\\cline{2-3}\cline{5-6}
&\parbox{\wcB}{\vspace{3pt}\noindent
686\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
arf gtpase-activating protein. [source:refseq;acc:nm\_133446]\vspace{3pt}}&&\multirow{2}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
Subtracted\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcF}{\vspace{3pt}\noindent
29\vspace{3pt}}}&\\\cline{2-3}
&\parbox{\wcB}{\vspace{3pt}\noindent
688\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
up-regulated in liver cancer 1; similar to development- and differentiation-enhancing factor 2. [source:refseq;acc:nm\_017707]\vspace{3pt}}&&&&\\\hline
\multirow{2}{*}{\parbox{\wcA}{\vspace{3pt}\noindent
37.4843\vspace{3pt}}}&\parbox{\wcB}{\vspace{3pt}\noindent
89\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
suppressor of actin 1. [source:refseq;acc:nm\_014016]\vspace{3pt}}}&\multirow{4}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
High confidence\vspace{3pt}}}&\parbox{\wcE}{\vspace{3pt}\noindent
Divided\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.58781\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcG}{\vspace{3pt}\noindent
23.6076\vspace{3pt}}}\\\cline{2-2}\cline{5-6}
&\parbox{\wcB}{\vspace{3pt}\noindent
446\vspace{3pt}}&&&\parbox{\wcE}{\vspace{3pt}\noindent
Subtracted\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
13.8767\vspace{3pt}}&\\\cline{1-3}\cline{5-7}
\multirow{2}{*}{\parbox{\wcA}{\vspace{3pt}\noindent
37.693\vspace{3pt}}}&\parbox{\wcB}{\vspace{3pt}\noindent
73\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
protein phosphatase inhibitor 2 (ipp-2). [source:swissprot;acc:p41236]\vspace{3pt}}}&&\parbox{\wcE}{\vspace{3pt}\noindent
Divided\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.73233\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcG}{\vspace{3pt}\noindent
65.2968\vspace{3pt}}}\\\cline{2-2}\cline{5-6}
&\parbox{\wcB}{\vspace{3pt}\noindent
400\vspace{3pt}}&&&\parbox{\wcE}{\vspace{3pt}\noindent
Subtracted\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
27.6038\vspace{3pt}}&\\\hline
\multirow{4}{*}{\parbox{\wcA}{\vspace{3pt}\noindent
39.8063\vspace{3pt}}}&\parbox{\wcB}{\vspace{3pt}\noindent
25\vspace{3pt}}&\multirow{4}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
lim domain binding 1; carboxy terminal lim domain protein 2; lim domain-binding factor-1. [source:refseq;acc:nm\_003893]\vspace{3pt}}}&\parbox{\wcD}{\vspace{3pt}\noindent
Low confidence\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
Divided\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcF}{\vspace{3pt}\noindent
3.15402\vspace{3pt}}}&\multirow{4}{*}{\parbox{\wcG}{\vspace{3pt}\noindent
12.6208\vspace{3pt}}}\\\cline{2-2}\cline{4-4}
&\parbox{\wcB}{\vspace{3pt}\noindent
33\vspace{3pt}}&&\multirow{2}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
High confidence\vspace{3pt}}}&&&\\\cline{2-2}\cline{5-6}
&\parbox{\wcB}{\vspace{3pt}\noindent
402\vspace{3pt}}&&&\multirow{2}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
Subtracted\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcF}{\vspace{3pt}\noindent
27.1855\vspace{3pt}}}&\\\cline{2-2}\cline{4-4}
&\parbox{\wcB}{\vspace{3pt}\noindent
700\vspace{3pt}}&&\parbox{\wcD}{\vspace{3pt}\noindent
Low confidence\vspace{3pt}}&&&\\\hline
nd{longtable}

Legend:
- Rank is the rank after comparing the two networks

 - Gene is the ensembl human gene identifier measured by 1 or more probes on the microarray

 - Value Type describes how the microarray measurement was processed. Ranked indicates that we sorted all measurements and use the rank as red and green value. Measured is the normal measurement. Squared and Rooted are the square and square root respecitcely. This might be valueable to compensate for non linear light distributions.

 - Network Comparison Type describes whether we divided the red and green types or whether we sutractcted them

 - Interaction Map specifies whether we used only the hig hconfidence protein-protein interactions or also included the low confidence interactions.

 - Filtered specifies whether we only included the high confidence microarry measurements or not.
- http://analysis.yellowcouch.org/